Change in the content of hepatic CYP by treating rats with PB and/or PK11195
| Treatment | CYP Content | Relative to Control | Relative to PB |
|---|---|---|---|
| nmol/mg protein | |||
| Experiment A | |||
| None (N = 3) | 1.29 ± 0.27 | 1 | |
| PB × 1 (N = 3) | 1.97 ± 0.041-150 | 1.53 | 1 |
| PK11195 (5 mg/kg) × 1 (N = 3) | 1.55 ± 0.19 | 1.20 | 0.79 |
| [PB + PK11195 (5 mg/kg)] × 1 (N = 4) | 2.11 ± 0.321-150 | 1.63 | 1.07 |
| [PB + PK1195 (25 mg/kg)] × 1 (N = 3) | 2.18 ± 0.131-150 | 1.69 | 1.11 |
| Experiment B | |||
| None (N = 3) | 1.45 ± 0.06 | 1 | |
| PB × 4 (N = 3) | 2.83 ± 0.331-150 | 1.95 | 1 |
| PK11195 (5 mg/kg) × 4 (N= 3) | 1.67 ± 0.101-150 | 1.15 | 0.59 |
| [PB + PK11195 (5 mg/kg)] × 4 (N = 3) | 3.83 ± 0.181-150,1-153 | 2.64 | 1.53 |
| [PB + PK11195 (25 mg/kg)] × 4 (N = 4) | 3.76 ± 0.161-150,1-153 | 2.59 | 1.33 |
In Experiment A, PB (80 mg/kg) and/or PK11195 (the dose indicated in the table) were given once to rats. In Experiment B, PB and/or PK11195 were given to rats for 4 consecutive days.
↵1-150 Significantly different from the control (P < 0.05).
↵1-153 Significantly different from the PB-treated group (P < 0.05).